SCLC is the most malignant type of lung cancer with high mortality and rapid development of drug resistance. In clinical treatment of non-small-cell lung cancer (NSCLC), therapeutics targeting known oncogenetic drivers such as epidermal growth factor receptor (EGFR) and ALK are proven effective,...
Moreover, in fast drug sensitivity assay, THZ1 and LY2228820 combination killed more lung adenocarcinoma cells from the PDX model than each drug alone (Fig. 4f). In addition, THZ1 and LY2228820 synergistically decreased the MYC protein and mRNA levels in A549 and H292 cells (Fig. 4g, h)....
Drug responses were measured using growth assays. ABCB1 was upregulated in ICEC0942-resistant cells and there was cross-resistance to THZ1. THZ1-resistant cells upregulated ABCG2 but remained sensitive to ICEC0942. Drug resistance in both cell lines was reversible upon inhibition of ABC-...
Drug resistance in both cell lines was reversible upon inhibition of ABC-transporters. CDK7i response was altered in adriamycin- and mitoxantrone-resistant cell lines demonstrating ABC-transporter upregulation. ABCB1 expression correlated with ICEC0942 and THZ1 response, and ABCG2 expression with THZ2...
For analysis of synergy between THZ1 with ABT-263, cells were treated with single drugs or different drug combinations for 48 h and cell viability was determined by the CCK-8 assay. The combination index (CI) was determined using CompuSyn software17. CI<1 indicates synergism. BrdU cell ...
Drug resistanceApoptosisCell cyclemTOR inhibitorCDK7 cyclin-dependent kinase 7CTD carboxyl-terminal domainICI immune checkpoint inhibitormRCC metastatic RCCRCC renal cell carcinomaRenal cell carcinoma (RCC) is a major cancer of the kidney. The 5-year survival rate is overall 74% and only 8% for ...
Cancer stem cellCisplatinDrug resistanceUrothelial carcinoma (UC) is the most common type of bladder cancer, with a 5-year survival rate of only 4.6% in metastatic UC. Despite the advances related to immune-checkpoint inhibitor therapy, chemotherapy remains the standard of care for metastatic ...